FDA Accepts Review of Samsung Bioepis and Biogen’s Ranibizumab Biosimilar (JSON)

lexblog.com/lib/010FKH8Mview recordjson

{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "FDA Accepts Review of Samsung Bioepis and Biogen’s Ranibizumab Biosimilar",
    "url": "https://www.lexblog.com/2020/12/02/fda-accepts-review-of-samsung-bioepis-and-biogens-ranibizumab-biosimilar/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-010FKH8M",
        "url": "https://www.lexblog.com/lib/010FKH8M/"
    },
    "datePublished": "2020-12-02T09:21:08-05:00",
    "dateModified": "2020-12-02T06:21:17-05:00",
    "author": {
        "@type": "Person",
        "name": "Grant B. Lukas"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Rothwell Figg"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Biosimilars Law Bulletin",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://www.biosimilarsip.com/?p=5396",
    "sourceStability": "may-move"
}